LP
Lucid Peptides
Research Grade

Research Summary

Cerebrolysin

Research Hub
Clinical — 10 studies

Cerebrolysin is a peptide mixture derived from porcine brain proteins studied in neuroprotective and neurotrophic research.

Being studied for

Neuroprotection researchCognitive recovery modelsNeurotrophic signaling

Published Research

Evidence profile

Preclinical, with limited uncontrolled human reports

10 cited publications

Findings below belong to the studies that reported them. They describe the material and conditions those authors used, not this product, and not an outcome to expect.

Supporting evidence

ReviewMeta-analysis

Cerebrolysin after moderate to severe traumatic brain injury: prospective meta-analysis of the CAPTAIN trial series

Vester JC et al. · Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology · 2021

The study reportedThe meta-analysis of the CAPTAIN trials confirms the safety and efficacy of Cerebrolysin after moderate-severe TBI, opening a new horizon for neurorecovery in this field. Integration of Cerebrolysin into existing guidelines should be considered after careful review of internationally applicable criteria.

PMID 33620612DOI 10.1007/s10072-020-04974-6
View on PubMed
ReviewMeta-analysis

Cerebrolysin for acute ischaemic stroke

Ziganshina LE et al. · The Cochrane database of systematic reviews · 2020

The study reportedModerate-quality evidence indicates that Cerebrolysin probably has little or no beneficial effect on preventing all-cause death in acute ischaemic stroke, or on the total number of people with serious adverse events. Moderate-quality evidence also indicates a potential increase in non-fatal serious adverse events with Cerebrolysin use.

PMID 32662068DOI 10.1002/14651858.CD007026.pub6NCT00868283
View on PubMed
ReviewMeta-analysis

Cerebrolysin for vascular dementia

Cui S et al. · The Cochrane database of systematic reviews · 2019

The study reportedCourses of intravenous Cerebrolysin improved cognition and general function in people living with vascular dementia, with no suggestion of adverse effects. However, these data are not definitive. Our analyses were limited by heterogeneity, and the included papers had high risk of bias.

PMID 31710397DOI 10.1002/14651858.CD008900.pub3NCT00947531
View on PubMed
ReviewMeta-analysis

Cerebrolysin for acute ischaemic stroke

Ziganshina LE et al. · The Cochrane database of systematic reviews · 2017

The study reportedThe findings of this Cochrane Review do not demonstrate clinical benefits of cerebrolysin for treating acute ischaemic stroke. We found moderate-quality evidence of an increase in non-fatal SAEs with cerebrolysin use but not in total SAEs.

PMID 28430363DOI 10.1002/14651858.CD007026.pub5
View on PubMed
ReviewMeta-analysis

Cerebrolysin for functional recovery in patients with acute ischemic stroke: a meta-analysis of randomized controlled trials

Wang Z et al. · Drug design, development and therapy · 2017

The study reportedIn conclusion, routine administration of cerebrolysin to patients with AIS cannot be supported by the available evidence from RCTs.

PMID 28458521DOI 10.2147/DDDT.S124273
View on PubMed
ReviewMeta-analysis

Cerebrolysin in mild-to-moderate Alzheimer's disease: a meta-analysis of randomized controlled clinical trials

Gauthier S et al. · Dementia and geriatric cognitive disorders · 2015

The study reportedThis meta-analysis provides evidence that Cerebrolysin has an overall beneficial effect and a favorable benefit-risk ratio in patients with mild-to-moderate AD. Cerebrolysin as a therapeutic agent should be considered by clinicians seeking treatment options for mild-to-moderate AD.

PMID 25832905DOI 10.1159/000377672
View on PubMed
ReviewMeta-analysis

Cerebrolysin for vascular dementia

Chen N et al. · The Cochrane database of systematic reviews · 2013

The study reportedCerebrolysin may have positive effects on cognitive function and global function in elderly patients with vascular dementia of mild to moderate severity, but there is still insufficient evidence to recommend Cerebrolysin as a routine treatment for vascular dementia due to the limited number of included trials, wide variety of treatment durations and short-term follow-up in most of the trials.

PMID 23440834DOI 10.1002/14651858.CD008900.pub2
View on PubMed
Additional indexed literature (3)

Published studies summarised here concern the specific investigational or pharmaceutical materials and study conditions described by their authors. Their findings are not performance claims for Lucid Peptides material. Citations verified against PubMed on 2026-08-09.

Cerebrolysin is used in specific regional research and clinical contexts and is not approved in all jurisdictions.

View full peptide profile for Cerebrolysin
All Research
[Notice]All information on this page is provided strictly for laboratory research and educational purposes only.